Organization (Industry)
Tetraphase Pharmaceuticals (United States)
ClinicalTrials.gov lists Tetraphase Pharmaceuticals (United States) as lead sponsor of 16 trials. It has 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Tetraphase Pharmaceuticals (United States): 16 lead-sponsored trials and 1 legal-entity registration.
Disease areas (2)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Kidney Failure, Chronic | 1 |
| Renal Insufficiency, Chronic | 1 |
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 4 |
| 2012 | 1 |
| 2011 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Eravacycline | 8 |
| Ertapenem | 3 |
| Levofloxacin | 2 |
| MEROPENEM | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=6) | 1 of 4 on time (n=4) |
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Antimicrobial agents and chemotherapy | 2 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 1 |
| Future microbiology | 1 |
| JAMA surgery | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 17 | 2 | 2025-04-08 |
Financing and grant events (1)
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2020-01-24 | Private placement | 9,997,939 | Form d |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| PRA Health Sciences | Uses vendor | 1 |
Latest dated events (35)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-05-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-04-08 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-02-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2021-03-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2021-02-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 35 events.
Biomarker capability evidence (16)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ZDHHC2 | Trial sponsor | Named in trial inclusion criteria |
| BTBD8 | Trial sponsor | Named in trial exclusion criteria |
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| GGT1 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 16 evidence rows.
On Scientist.com
Tetraphase Pharmaceuticals (United States) is listed as a research supplier in the Scientist.com network.
Service areas
Tetraphase Pharmaceuticals is a clinical-stage life science company with a synthetic chemistry technology platform that has the power to address the global health crisis caused by antibiotic resistance. Since the company’s inception in late 2006, Tetraphase has developed a robust antibiotics platform based on the tetracycline core, which offers the potential to dramatically improve the treatment of both broad and selective spectrum bacterial infections. Tetracyclines are proven antibacterial agents and represent one of the most trusted classes of antibiotics. To date, all commercial...
Show the full description
Tetraphase Pharmaceuticals is a clinical-stage life science company with a synthetic chemistry technology platform that has the power to address the global health crisis caused by antibiotic resistance. Since the company’s inception in late 2006, Tetraphase has developed a robust antibiotics platform based on the tetracycline core, which offers the potential to dramatically improve the treatment of both broad and selective spectrum bacterial infections.
Tetracyclines are proven antibacterial agents and represent one of the most trusted classes of antibiotics. To date, all commercial tetracycline antibiotics have been prepared by fermentation-semisynthesis, which is an inherently limited process. Tetraphase’s fully synthetic approach provides new avenues for the discovery and development of novel and potent antibiotics with unique profiles. Tetraphase has leveraged this powerful new approach, which was pioneered at Harvard, to produce a pipeline of novel tetracycline antibiotics.
Tetraphase is rapidly advancing its clinical pipeline of potent novel antibiotics. In terms of spectrum, potency, efficacy, safety and dosing convenience/flexibility, Tetraphase’s pipeline offers significant differentiation from currently marketed products for the treatment of serious infections as well as from those in development by other companies.
- Website
- www.tphase.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Tetraphase on Scientist.com
For prices, more details, or to contact Tetraphase, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.